
|Articles|October 1, 2003
Supplements and Featured Publications
- Biopharmaceutical Agents for Treating Rheumatoid Arthritis: Impact on Patients and Managed Care Heal
- Volume 9
- Issue 6 Suppl
Treatment Compliance and Dosage Administration Among Rheumatoid Arthritis Patients Receiving Infliximab, Etanercept, or Methotrexate
Advertisement
Articles in this issue
about 22 years ago
Participating Facultyabout 22 years ago
Defining and Characterizing the Late-stage Biopharmaceutical PipelineNewsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Bills to Address Expiring ACA Subsidies Fail to Pass Senate
2
Clascoterone 5% Delivers Strong Phase 3 Results for Androgenetic Alopecia
3
Pirtobrutinib Outperforms Bendamustine-Rituximab in Frontline CLL/SLL
4
In CLL, New Therapies Offer Potential for Personalized Approaches
5










































